During AML development, the repertoire of NK cells is modified, reducing the expression of activating receptors, NKG2D, DNAX accessory molecule-1 (DNAM-1), natural cytotoxicity triggering receptor 3 (NKp30), NKp46 (41), and increasing that of inhibitory receptors, killer Ig-like receptors (KIRs), and natural killer group 2A (NKG2A). This evidence concerns the gene CD226 and acute myeloid leukemia.